Related Experiment Videos
[Trimetazidine and degenerative deafness. Effect on hearing and integration]
J P Haguenauer1, J P Bebear, L R Bordes
1Service d'Oto-Rhino-Laryngologie, Hôpital de la Croix-Rousse, Lyon.
Summary
Trimetazidine at 60 mg/day significantly improved hearing in patients with degenerative hearing loss. This treatment enhanced audibility, speech intelligibility, and reduced the social impact of hearing impairment.
Area of Science:
- Otolaryngology
- Pharmacology
- Audiology
Background:
- Degenerative hearing loss affects a significant portion of the population.
- Current management strategies for sensorineural hearing loss have limitations.
- Trimetazidine is being investigated for its potential otoprotective effects.
Purpose of the Study:
- To evaluate the efficacy of trimetazidine in patients with degenerative hearing loss.
- To assess the impact of trimetazidine on audibility, speech intelligibility, and quality of life.
Main Methods:
- A 6-month, multicenter, double-blind, placebo-controlled trial.
- Involved 251 patients with bilateral symmetrical sensorineural hearing loss.
- Assessed outcomes using pure-tone audiometry, speech audiometry, and subjective patient evaluations.
Main Results:
- Trimetazidine (60 mg/day) showed significant improvements in audibility in the acute frequency range (p = 0.002).
- Speech intelligibility was significantly enhanced in the trimetazidine group (p = 0.008).
- Patients receiving trimetazidine reported better subjective hearing and reduced social impact of hearing loss.
Conclusions:
- Trimetazidine is an effective treatment for degenerative hearing loss.
- The drug demonstrates benefits across objective audiometric measures and subjective patient-reported outcomes.
- Trimetazidine facilitates better social integration by improving hearing and reducing the psychological impact of hearing impairment.